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Abstract
This review will discuss some issues related to the risk/benefit profile of the use of dietary
antioxidants. Thus, recent progress regarding the potential benefit of dietary antioxidants in the
treatment of chronic diseases with a special focus on immune system and neurodegenerative
disorders will be discussed here. It is well established that reactive oxygen species (ROS) play an
important role in the etiology of numerous diseases, such as atherosclerosis, diabetes and cancer.
Among the physiological defense system of the cell, the relevance of antioxidant molecules, such
as glutathione and vitamins is quite well established. Recently, the interest of researchers has, for
example, been conveyed on antioxidant enzyme systems, such as the heme oxygenase/biliverdin
reductase system, which appears modulated by dietary antioxidant molecules, including
polyphenols and beta-carotene. These systems possibly counteract oxidative damage very
efficiently and finally modulate the activity of oxidative phenomena occurring, for instance, during
pathophysiological processes. Although evidence shows that antioxidant treatment results in
cytoprotection, the potential clinical benefit deriving from both nutritional and supplemental
antioxidants is still under wide debate. In this line, the inappropriate assumption of some lipophylic
vitamins has been associated with increased incidence of cancer rather than with beneficial effects.
Introduction
The term "free radicals" designates a family of compounds
characterized by great reactivity due to the impaired elec-
tron in the outer orbital. To this group belong reactive
oxygen species (ROS), such as superoxide anion, hydroxyl
radical and hydrogen peroxide, as well as reactive nitrogen
species (RNS) which include nitric oxide and peroxyni-
trite. Although structurally different, free radicals share
similar mechanisms to harm body's cells and tissues
through damage on proteins, DNA and lipids [1]. The
alterations of membrane functions occurring as a conse-
quence of phospholipid modifications represent a rele-
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considering the organism as a whole, or a specific inte-
grated function, such as the immune response [2]. The
potential therapeutic applications of antioxidants in free
radical-related diseases led to the hypothesis of their use
to slow down or reverse, for example, symptoms associ-
ated with with neurodegenerative disorders, such as
Alzheimer's disease (AD), Parkinson's disease (PD), or
spongiform encephalopathies. Such effect could occur
through a block of proinflammatory cytokines action and
the resulting oxidative damage [3-7]. However, several
clinical studies demonstrated that not only malnutrition,
but also the excess of certain nutrients (e.g. iron, alpha-
tocopherol, beta-carotene, ascorbic acid) may set into
motion oxidation phenomena and, therefore, cell injury
[8,9]. Thus, it is of relevance that prior to considering
introducing antioxidant therapy into mainstream medi-
cine, significant advances in basic cell biology, pharma-
cology and clinical bioanalysis will be required.
Oxidative Stress
The body is normally under a dynamic equilibrium
between free radical generation and quenching. The phys-
iological defense systems to counteract free radicals
encompass endogenous enzyme systems, such as catalase,
glutathione reductase and superoxide dismutase, as well
as glutathione, urate and coenzyme Q, or exogenous fac-
tors (β-carotene, vitamin C, vitamin E and selenium) [10].
All these molecules have an antioxidant effect due to their
ability to transform ROS into stable and harmless com-
pounds or by scavenging both ROS and RNS with a redox-
based mechanism [10]. Very recently, a main role in the
fight against oxidative stress has been assumed by
enzymes such as heme oxygenase (HO) and biliverdin
reductase (BVR). Heme oxygenase is a microsomal
enzyme which metabolizes heme into ferrous iron, car-
bon monoxide and biliverdin (BV); the latter is then
reduced by BVR into bilirubin (BR), a molecule endowed
with strong antioxidant and antinitrosative activities [11-
14]. Interestingly, all these protective factors act in a con-
certed way, enhancing the antioxidant defense system of
the cell. When the balance between ROS/RNS and antioxi-
dants turns in favor of the former, oxidative/nitrosative
stress occurs. Although oxidative stress is associated with
most diseases, routine assay methods are not nowadays
available in the clinical practice. A strategy widely used to
determine oxidative stress is measurement of malonyldi-
aldehyde, F2-isoprostanes, or 8-hydroxydesoxyguanosine.
Actually, these molecules are regarded as the most reliable
markers available [15]. A classic example of an oxidation
product apparently leading to disease, is oxidized choles-
terol in low-density lipoprotein (LDL), which displays a
higher atherogenic potential than native LDL, and mainly
involved in the pathogenesis of atherosclerosis and coro-
nary heart disease (CHD) [16].
At the cellular level, a large body of data clearly demon-
strated that ROS, when produced in low amounts and in
a controlled manner, are physiological components of the
signalling generated by cytokines, growth factors and neu-
rotrophic peptides [17-22], although they may also acti-
vate apoptotic cell death [23]. Extracellularly generated
ROS can diffuse through anion channels into the cyto-
plasm; the resulting variation in the cell redox state leads
to modulation of an array of transcription factors (eg. NF-
kB, AP-1), protein kinases (e.g. AKT, JNK, p38), and recep-
tor activated MAP kinases involved in apoptosis [17,24-
26]. Moreover, the proapoptotic molecules Fas and Fas
ligand (FasL) undergo positive transcriptional regulation
after exposure to oxidants [27]. Interestingly, Krammer
and Colleagues demonstrated that in vitro administration
of vitamin E suppresses FasL mRNA expression and pro-
tects T cells of HIV-1 infected individuals from Fas medi-
ated apoptosis [28]. Moreover, it was demonstrated that
administration of combinations of vitamin E and C to cul-
tures of human umbilical vein endothelial cells (HUVEC)
treated with lipopolysaccharide could prevent apoptosis
by upregulation of Bcl-2 [29].
Antioxidants, The Immune System And Related Disorders
The protective function against external pathogens carried
out by the immune system is by itself a source of ROS,
since activated neutrophils, produce free radicals to a sig-
nificant extent [30]. Moreover, during the inflammatory
process, activation of phagocytes through the interaction
of proinflammatory mediators, or bacterial products with
specific receptors results in the assembly of the multicom-
ponent flavoprotein NADPH oxidase which catalyzes the
production of large quantities of the superoxide anion
radical (O2 -) [31]. In addition to classical reactive oxygen
metabolites, activated neutrophils and monocytes release
the hemoprotein myeloperoxidase (MPO) into the extra-
cellular space, where it catalyzes the oxidation of Cl- by
H2O2 to yield hypochlorous acid (HClO) [32]. HClO is a
non-specific oxidizing and chlorinating agent that reacts
rapidly with a variety of biological compounds, such as
sulphydryls, polyunsatured fatty acids, DNA, pyridine
nucleotides, aliphatic and aromatic aminoacids and nitro-
gen-containing compounds [33-35]. Moreover, apart
from their direct toxic effects, neutrophil-derived oxidants
may promote tissue injury indirectly by altering the pro-
tease/antiprotease equilibrium that normally exists within
the intestinal interstitium. The oxidative inactivation of
important protease inhibitors, coupled to the oxidant-
mediated activation of latent proteases, creates a favorable
environment for neutrophils that allows degradation of
the interstitial matrix through elastases, collagenases and
gelatinases, as well as injury to epithelial cells [36,37].
However, not only immune cell produce ROS necessary
for the microbicidal activity, but they are also sensitive to
external ROS, due to their high polyunsaturated fattyPage 2 of 9
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pared with other somatic cells, in that they contain high
levels of antioxidant vitamins, presumably providing pro-
tection against lipid peroxidation and immunosuppres-
sion, both of which are well known risks posed by high
PUFA content [38]. The reactivity of immune cells to exog-
enous ROS has been shown to be age-dependent. In fact,
lymphocytes from elderly individuals appear to be more
sensitive to exposure to hydrogen peroxide than those
from young adults [39]. Moreover, it has been demon-
strated that a micronutrient deficiency can be the cause of
suppression of immune function affecting both innate T-
cell-mediated immune response and adaptive antibody
response, thus altering the balanced host response. There-
fore, an adequate intake of vitamins and antioxidant ele-
ments seems to be essential for an efficient function of the
immune system. Micronutrient deficiency occurs in vari-
ous conditions, such as eating disorders, tobacco smokers,
chronic diseases, aging. During aging, changes in the
immune system are frequent and associated with
increased susceptibility to infections. Antioxidant vita-
mins and trace elements contribute to maintain an effec-
tive immune response [40]. For example, administration
of vitamin E supplement to healthy elderly patients pro-
duced an increased antibody titer to both hepatitis B and
tetanus vaccine [41], thus enhancing T-cell mediated func-
tions. In conclusion, maintaining adequate antioxidant
status may provide a useful approach in attenuating cell
injury and dysfunction observed in some inflammatory/
autoimmune disorders [42,43].
Autoimmunity has been for decades considered the result
of a breakdown in self-tolerance. At the present, it is
known that autoimmunity is a physiological process [44].
This phenomenon becomes pathological when the
number of autoreactive cells, and particularly the avidity
of their receptors for autoantigens, increases [44]. Trigger-
ing of the disease usually depends both on the increase in
immunogenicity of the target cell, which may be second-
ary to a viral infection (Chediak-Higashi syndrome and
Griscelli syndrome by EBV), and on the individual's own
capacity to recognize the autoantigens (HLA, or T cell rep-
ertoire in Familial hemophagocytic lymphohistiocytosis
[FHL]) [45]. Moreover, apart from the genetic defects that
may predispose to autoimmune diseases, one must take
into account the environmental factors that are implicated
in the development of such pathologies. Among them, an
important role is played by xenobiotics such as chemicals,
drugs and metals [46]. Iron, aluminum, and manganese
readily cross the blood brain barrier via specific or non-
specific carriers, and contribute to the nervous tissue dam-
age [47,48]. The toxic effects of metals are mediated
through free radical formation, or enzyme inhibition [49-
53]. In addition, metals may act as immunosuppressants
(cytostatically), or as immunoadjuvants (through non-
specific activation of the immune response) [54,55]. Sev-
eral mechanisms are proposed on how metals may act
within the immune system to induce autoimmunity.
Patients suffering from scleroderma develop autoantigens
with metal-binding sites. After metal binding, free radical
species are generated which fragment auto-antigens
thereby exposing cryptic epitopes, which may then trigger
autoimmunity [56,57]. Taken together, these findings
underlie the importance of exogenous factors in the
pathogenesis of autoimmunity. Nevertheless, all these ele-
ments do not appear sufficient to provoke chronic autoim-
mune diseases such as Multiple Slerosis (MS), myasthenia
gravis, Insulin Dependent Diabetes Mellitus (IDDM) or
Hashimoto's thyroiditis, and the passage to chronic dis-
ease is usually secondary to a defect in immunoregula-
tion.
Several classes of regulatory T cells, such as Th2, CD25+
and natural killer (NK) T cells, are implied in autoim-
mune pathologies. In an animal model of a Th2-domi-
nated autoimmune syndrome, the administration of the
antioxidant N-acetyl-cysteine (NAC) induced a decrease
in mast-cell expression of both IgE and IL-4 [58]. Of major
interest is the discovery of the therapeutic potential of a
new benzoquinone-containing product derived from
wheat germ fermentation. This latter has been shown to
have immune restorative properties because it affects the
Th1/Th2 network by inhibiting the Th2 response [59].
Another beneficial effect of this molecule is its anti-meta-
static activity, shown in various human malignancies and
Jurkat leukemia cell line [60]. Intriguingly, the combined
treatment with wheat germ and vitamin C profoundly
inhibited metastasis formation in various tumor models
of different origin (Lewis lung carcinoma, B16 melanoma
and human colon carcinoma xenografts [HCR25]) [61].
On the contrary, wheat germ had no toxicity on peripheral
blood leukocytes (PBLs) at doses that affected tumor cells.
The crude powder extract of fermented wheat germ inhib-
its nucleic acid ribose synthesis primarily through the
non-oxidative steps of the pentose cycle [60]. Curiously,
another quinone compound, carnosic acid quinone, like
wheat germ, recovers potent antioxidant activity upon
standing [62].
Keeping in mind the importance of oxidative stress in the
regulation/dysregulation of immune system, the use of
antioxidants in such diseases has been reasonably pro-
posed. Rheumatoid arthritis (RA) is a classic example of
autoimmune disease. Joint inflammation in rheumatoid
arthritis (RA) is characterized by invasion of T cells in the
synovial space and proliferation of activated macrophages
and fibroblasts in the synovial intima [63]. Therefore, in
the rheumatic joint there is an increased activity of fibrob-
lasts and leucocytes which produce ROS [64,65]. Very
recently, antioxidants have been successfully used as adju-Page 3 of 9
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with RA seemed to be very promising, the indiscriminate
use of antioxidants in autoimmune disorders is not rec-
ommended. In fact, autoimmune lymphoproliferative
syndrome (ALPS), MS, type 1 diabetes and multiple
autoimmune syndrome, have been linked to decreased
Fas functionality [68] and, as discussed previously, anti-
oxidants may up-regulate Fas and FasL in vitro. Increasing
evidence provides support that oxidative stress and apop-
tosis are closely related physiological phenomena and are
implicated in diseases including autoimmune diseases.
Therefore molecules that target both apoptosis-related sig-
nal transduction and oxidative stress, like antioxidants,
are likely to result in the improvement of these patholo-
gies.
A novel possible approach to modulate immune system
thus preventing autoimmunity or transplant rejection is
the activation of cytoprotective and antioxidant enzymes
such as HO-1. Heme oxygenase-1, the inducible isoform
of HO, is a key protein in the cell stress response and its
up-regulation is a common event during pro-inflamma-
tory conditions [11,69-72]. Recent work clearly demon-
strated that regulatory T cells overexpress HO-1 and
release CO under pro-oxidant conditions. Carbon mon-
oxide may inhibit the proliferation of effector T cells, thus
reducing the immune response and prevent autoimmu-
nity and/or graft reaction [73,74]. Dietary antioxidants, in
particular polyphenols, has been shown to increase HO-1
expression in different in vitro systems [3,75,76] and the
potential use of this natural substances to regulate
immune response should be carefully addressed.
Antioxidants, Cancer And Neurodegenerative Disorders
It is well known that the dietary consumption of fruits,
vegetables, herbs, or their phytochemical constituents aid
in cancer prevention [77-79]. It is believed that the anti-
oxidant properties of such foods protect cells from ROS-
mediated DNA damage that can result in mutation and
subsequent carcinogenesis. ROS-induced DNA damage
can take many forms, ranging from specifically oxidized
purine and pyrimidine bases, to DNA lesions such as
strand breaks, sister chromatid exchanges (SCEs), and the
formation of micronuclei [80]. However, the equation
"antioxidant = benefit" is not always true. In vivo experi-
ments demonstrated that retinol increases both the
humoral and the cell-mediated immune response and
could enhance immune surveillance against tumorigene-
sis [81-83]. Retinol may influence the immune response
by quenching free radicals, which could lower the level of
immunosuppressing lipid peroxides, alter arachidonic
acid metabolism, etc. [82,84]. In the last few years many
studies have been conducted to investigate the effects of
vitamins on disease prevention. The first results have been
encouraging and a wide number of people are taking anti-
oxidant supplements with the aim to improve their
health. These studies, initially, have shown that a high
consumption of fruit and vegetables decreases risks of
lung cancer in healthy individuals and a combination of
β-carotene, vitamin E and selenium reduced stomach can-
cer mortality in China [85,86]. Conversely, supplemental
β-carotene alone or in combination with retinol or vita-
min E did not have any effect on cancer risk, or increased
the development of lung cancer in smokers [87,88]. In the
light of these first contrasting result, and also as a conse-
quence of the wide antioxidant consumption in the gen-
eral population, various systematic reviews to estimate the
association between antioxidant use and disease preven-
tion, in particular for primary cancer incidence and mor-
tality, have been issued. These reviews share the opinion
that antioxidant supplementation per se does not prevent
cancer. On the contrary, some antioxidant elements seem
to be harmful fro health. Recent studies have confirmed
the relationship between beta-carotene and an increased
incidence of cancer among smokers, but not among non-
smokers. Moreover, beta carotene supplementation is
associated with increased cancer-related mortality [89].
Vitamin E treatment also appears to be associated with a
slightly increased incidence of lung cancer [90]. Other
studies report that combination of vitamin A and other
antioxidants, significantly increases mortality related to
neoplastic diseases [91]. According to these studies, sele-
nium would be the only element displaying beneficial
effects, as it has been shown that it reduces total cancer
incidence, an apparently sex-related effect, as it is predom-
inant among males, rather than in females [89].
The reason why β-carotene may exert dual activity, namely
antioxidant or pro-carcinogenic has been debated for
quite a long time. The first hypothesis is that at high con-
centrations, β-carotene stimulates free radical production,
whereas at lower concentrations β-carotene exerts antioxi-
dant activity [90,91]. Furthermore, in the presence of cig-
arette smoke-derived free radicals β-carotene is cleaved
into many derivatives which are very unstable and may
trigger further oxidation [92-95]. A recent corollary to this
theory is the evidence that β-carotene, either alone or in
combination with cigarette smoke condensate, repressed
HO-1 expression both in rat fibroblasts and human lung
cancer cells [96]. The reduced expression of HO-1
accounted for a reduced production of CO and BR both of
which have a marked antiproliferative effects [96-100].
Vitamin E has also been shown to act at the immune sys-
tem level; in fact, supplementation with this vitamin can
increase production of antibodies and enhance cell-medi-
ated immunity in both experimental animals and in
humans [101].
Neurodegenerative diseases, such as Parkinson's disease
(PD), Alzheimer's disease (AD), and amyotrophic lateralPage 4 of 9
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gered, at least in part, by oxidative and nitrosative stress
and also sustained by inflammatory cytokine production
[11,70,102-104]. Similarly, autoimmunity mainly con-
tributes to the pathogenesis of MS, characterized by cen-
tral and peripheral loss of nerve myelin [105,106].
Although the specific sources of the damaging ROS and
the affected target structures differ between the neuronal
pathologies, the following general features can be defined.
Increased levels of oxidation-altered metabolites are
found in post-mortem tissues in many of the neurodegen-
erative diseases listed above [107-113]. An oxidative stress
response and compensatory defense reactions can be seen
in the affected neural cells; further, disturbances of the
mitochondrial metabolism are observed, which may
account for an increased leakage of ROS originating from
the respiratory chain [11,70,104,114]. However, in addi-
tion to the direct induction of oxidative stress, metabolic
disorders underlying every single disease can also indi-
rectly generate an oxidative microenvironment, for exam-
ple via the induction of a local immune response
[115,116]. On this basis, antioxidant and antinflamma-
tory drugs, such as polyphenols and non-steroidal antin-
flammatory drugs (NSAIDs), have been proposed in the
treatment of different neurodegenerative diseases [117-
119]. However, both polyphenols and NSAIDs gave rise
to some problems when used in clinical setting. Due to
their scarce bioavailability, only a negligible amount of
polyphenols reaches brain tissue and the concentrations
achieved are much lower than those efficacious in vitro
[3]. As far as NSAIDs, ad hoc designed clinical trials with a
large number of patients, clearly demonstrated that these
drugs do not have any significant effect in slowing cogni-
tive decline in patients suffering from mild-to-moderate
AD [120,121]. Similar disappointing results have been
obtained in the treatment of ALS, a systemic motor neu-
ron disease that affects corticospinal and corticobulbar
tracts, ventral horn motor neurons and motor cranial
nerve nuclei [122,123]. Approximately 10% of cases are
familial and have been linked to point mutation in the
gene encoding for Cu/Zn superoxide dismutase (SOD)
[124]. Mice transgenic for mutated SOD1 develop symp-
toms and pathologies similar to those in human ALS.
Mutant SOD1 toxicity is mediated by damage to mito-
chondria in motor neurons, and this may trigger the func-
tional decline of motor neurons and the onset of ALS in
mice [125]. Unfortunately, although the role played by
free radical to the pathogenesis of ALS has been demon-
strated, antioxidants did not have any effect to prevent or
slow down its progression. Desnuelle et al., clearly dem-
onstrated that alpha-tocopherol, given together with rilu-
zole, did not affect the survival and motor functions in
ALS patients respect to the group treated with riluzole
alone [126]. Novel compound, such as AEOL-10150
(Aeolus), structurally related to the SOD catalytic site, is
under phase I clinical investigation, but further clinical tri-
als will be necessary to evaluate the real efficacy of this
compound for the therapy of ALS [127,128].
Conclusion
The field of antioxidants is moving rapidly. About 20
years ago the hypothesis that diet might have a substantial
influence on the development of some pathologies, such
as cancer, has been raised by many scientists. In this light,
during the last decade, efforts have been made to analyze
the effects of plant food and synthetic antioxidants on the
development and prevention of chronic diseases. Nowa-
days, antioxidants are used on a large scale to try to obtain
and preserve optimal health. While there is no doubt that
the correct balance between endogenous and exogenous
antioxidant capacity is essential to life, the curative power
of antioxidants has often been overestimated. In fact,
according to the popular idea "if one is good two is bet-
ter", antioxidants are taken in excess too often and the risk
to originate diseases instead of preventing them is quite
high. It is noteworthy to underlie that as for all drugs, anti-
oxidants may give important side effects if not correctly
used or in combination with other drugs. Vitamin A, E
and β-carotene for instance, have been shown to have pro-
oxidant effects at higher doses or under certain conditions
[39].
Another point of criticism is the possibility to take exper-
imental results "from the bench to the bedside". In fact,
although the promising results obtained by in vitro exper-
iments, the use of antioxidants in the treatment of human
disease states has not been as successful as might have
been envisaged due to intrinsic pharmacokinetic or phar-
macodynamic limitations.
In addition, conclusions on beneficial effect of antioxi-
dant are often drawn from studies conducted with syn-
thetic antioxidant supplement, whereas fruits and
vegetable are a complex mixture of antioxidant, as well as
other potentially beneficial micronutrients and macronu-
trients, which may, thus, work with different kinetics and
dynamics [89].
In conclusion, the correct use of antioxidants may be use-
ful to prevent free radical-related disorders. However, the
repair of existing critical structural damage may be beyond
the possibilities of antioxidants and therefore they may
not be considered to be useful in therapeutic clinical
applications, where their limits and eventual side effects
must be better understood.
Competing interests
The authors declare that they have no competing interests.Page 5 of 9
(page number not for citation purposes)
Nutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/29Authors' contributions
DB & GC wrote the manuscript. MRS & GDB edited the
manuscript and did the work on references. CM contrib-
uted to the work with update of data on effects of antioxi-
dants. PB, SP & LL contributed to the literature as
recipients of a grant for the study of the effects of antioxi-
dants in cancer cells and in neurodegeneration models.
RB conceived of the study, and participated in its design
and coordination. All authors read and approved the final
manuscript.
Acknowledgements
The Authors acknowledge the Ph.D. School in Preclinical and Clinical Phar-
macology, University of Catania, Catania; the Co.Ri.Bi.A. Consortium, Pal-
ermo; Regione Siciliana, Assessorato per l'Agricoltura for their generous 
support.
References
1. Pauwels EK, Erba PA, Kostkiewicz M: Antioxidants: A tale of two
stories.  Drug News Perspect 2007, 20(9):579-585.
2. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free
radicals and antioxidants in normal physiological functions
and human disease.  Int J Biochem Cell Biol 2007, 39(1):44-84.
3. Mancuso C, Bates TE, Butterfield DA, Calafato S, Cornelius C, De
Lorenzo A, Dinkova Kostova AT, Calabrese V: Natural antioxi-
dants in Alzheimer's disease.  Expert Opin Investig Drugs 2007,
16(12):1921-1931.
4. Whitton PS: Inflammation as a causative factor in the aetiol-
ogy of Parkinson's disease.  Br J Pharmacol 2007, 150(8):963-976.
5. Ramassamy C: Emerging role of polyphenolic compounds in
the treatment of neurodegenerative diseases: a review of
their intracellular targets.  Eur J Pharmacol 2006, 545(1):51-64.
6. Pham DQ, Plakogiannis R: Vitamin E supplementation in Alzhe-
imer's disease, Parkinson's disease, tardive dyskinesia, and
cataract: Part 2.  Ann Pharmacother 2005, 39(12):2065-2072.
7. Drisko JA: The use of antioxidants in transmissible spongi-
form encephalopaties: a case report.  J Am Coll Nutr 2002,
21(1):22-25.
8. Fang Y, Yang S, Wu G: Free radicals, antioxidants and nutrition.
Nutrition 2002, 18(10):872.
9. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study
Group: The effect of vitamin E and beta carotene on the inci-
dence of lung cancer and other cancers in male smokers.  N
Engl J Med 1994, 330:1029-1035.
10. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals,
metals and antioxidants in oxidative stress-induced cancer.
Chem Biol Interact 2006, 160(1):1-40.
11. Mancuso C, Scapagnini G, Currò D, Giuffrida Stella AM, De Marco C,
Butterfield DA, Calabrese V: Mitochondrial dysfunction, free
radical generation and cellular stress response in neurode-
generative disorders.  Front Biosci 2007, 12:1107-1123.
12. Mancuso C, Pani G, Calabrese V: Bilirubin: an endogenous scav-
enger of nitric oxide and reactive nitrogen species.  Redox Rep
2006, 11(5):207-213.
13. Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G: Albumin-
bound bilirubin interacts with nitric oxide by a redox mech-
anism.  Antioxid Redox Signal 2006, 8(3–4):487-494.
14. Mancuso C, Bonsignore A, Di Stasio E, Mordente A, Motterlini R:
Bilirubin and S-nitrosothiols interaction: evidence for a pos-
sible role of bilirubin as a scavenger of nitric oxide.  Biochem
Pharmacol 2003, 66(12):2355-2363.
15. Grune T, Berger MM: Markers of oxidative stress in ICU clinical
settings: present and future.  Curr Opin Clin Nutr Metab Care 2007.
16. Gouni-Berthold I, Sachinidis A: Possible non-classic intracellular
and molecular mechanisms of LDL cholesterol action con-
tributing to the development and progression of atheroscle-
rosis.  Curr Vasc Pharmacol 2004, 2(4):363-370.
17. Bedogni B, Pani G, Colavitti R, Riccio A, Borrello S, Murphy M, Smith
R, Eboli ML, Galeotti T: Redox regulation of cAMP-responsive
element-binding protein and induction of manganous super-
oxide dismutase in nerve growth factor-dependent cell sur-
vival.  J Biol Chem 2003, 278:16510-16519.
18. Finkel T: Oxidant signals and oxidative stress.  Curr Opin Cell Biol
2003, 15(2):247-254.
19. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger
J, Galeotti T: Reactive oxygen species as downstream media-
tors of angiogenic signaling by vascular endothelial growth
factor receptor-2/KDR.  J Biol Chem 2002, 277:3101-3108.
20. Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T: A
redox signaling mechanism for density-dependent inhibition
of cell growth.  J Biol Chem 2000, 275:38891-38899.
21. Pani G, Colavitti R, Borrello S, Galeotti T: Endogenous oxygen
radicals modulate protein tyrosine phosphorylation and
JNK-1 activation in lectin-stimulated thymocytes.  Biochem J
2000, 347:173-181.
22. Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W:
Depletion of the mitochondrial electron transport abrogates
the cytotoxic and gene-inductive effects of TNF.  EMBO J 1993,
12:3095-3104.
23. Jabs T: Reactive oxygen intermediates as mediators of pro-
grammed cell death in plants and animals.  Biochem Pharmacol
1999, 57:231-245.
24. Hawkins BJ, Madesh M, Kirkpatrick CJ, Fisher AB: Superoxide flux
in endothelial cells via the chloride channel-3 mediates intra-
cellular signaling.  Mol Biol Cell 2007, 18(6):2002-2012.
25. Bubici C, Papa S, Dean K, Franzoso G: Mutual cross-talk between
reactive oxygen species and nuclear factor-kappa B: molec-
ular basis and biological significance.  Oncogene 2006,
25(51):6731-6748.
26. Cakir Y, Ballinger SW: Reactive species-mediated regulation of
cell signaling and the cell cycle: the role of MAPK.  Antioxid
Redox Signal 2005, 7(5–6):726-740.
27. Suhara T, Fukuo K, Sugimoto T, Morimoto S, Nakahashi T, Hata S,
Shimizu M, Ogihara T: Hydrogen peroxide induces up-regula-
tion of Fas in human endothelial cells.  J Immunol 1998,
160:4042-4047.
28. Weber ML, Weigand MA, Giaisi M, Suss D, Treiber MK, Baumann S,
Ritsou E, Breitkretz R, Krammer PH: Vitamin E inhibits CD95 lig-
and expression and protects T cell from activation-induced
cell death.  J Clin Invest 2002, 110:681-690.
29. Haendeler JH, Zeiher AM, Dimmeler S: Vitamin C and E prevent
lipopolysaccharide-induced apoptosis in human endothelial
cells by modulation of Bcl-2 and Bax.  Eur J Pharmacol 1996,
317:407-411.
30. Fialkow L, Wang Y, Downey GP: Reactive oxygen and nitrogen
species as signaling molecules regulating neutrophil func-
tion.  Free Radic Biol Med 2007, 42(2):153-164.
31. Behe P, Segal AW: The function of the NADPH oxidase of
phagocytes, and its relationship to other NOXs.  Biochem Soc
Trans 2007, 35(Pt 5):1100-1103.
32. Malle E, Furtmüller PG, Sattler W, Obinger C: Myeloperoxidase: a
target for new drug development?  Br J Pharmacol 2007,
152(6):838-854.
33. Messner MC, Albert CJ, Hsu FF, Ford DA: Selective plasmenyl-
choline oxidation by hypochlorous acid: formation of lyso-
phosphatidylcholine chlorohydrins.  Chem Phys Lipids 2006,
144(1):34-44.
34. Shen Z, Wu W, Hazen SL: Activated leukocytes oxidatively
damage DNA, RNA, and the nucleotide pool through halide-
dependent formation of hydroxyl radical.  Biochemistry 2000,
39(18):5474-5482.
35. Winterbourn CC, Berg JJ van den, Roitman E, Kuypers FA: Chloro-
hydrin formation from unsaturated fatty acids reacted with
hypochlorous acid.  Arch Biochem Biophys 1992, 296(2):547-555.
36. Rice WG, Weiss SJ: Regulation of proteolysis at the neutrophil-
substrate interface by secretory leukoprotease inhibitor.  Sci-
ence 1990, 249(4965):178-181.
37. Weiss SJ: Tissue destruction by neutrophils.  N Engl J Med 1989,
320:365.
38. Bendich A: Vitamin E and immune functions.  Basic Life Sci 1988,
49:615-620.
39. Lopez-Hellin J, Garcia-Arumi E, Schwartz S: Oxidative stress
induces age-dependent changes in lymphocyte protein syn-
thesis and second messenger levels.  Life Sci 1998, 63(1):13-21.Page 6 of 9
(page number not for citation purposes)
Nutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/2940. Wintergerst ES, Maggini S, Hornig DH: Contribution of selected
vitamins and trace elements to immune function.  Ann Nutr
Metab 2007, 51(4):301-23.
41. Meydani SN, Meydani M, Blumberg JB, Leka LS, Siber G, Loszewski R,
Thompson C, Pedrosa MC, Diamond RD, Stollar BD: Vitamin E
supplementation and in vivo immune response in healthy
elderly subjects. A randomised controlled trial.  JAMA 1997,
277(17):1380-1386.
42. De la Fuente M, Hernanz A, Vallejo MC: The immune system in
the oxidative stress conditions of aging and hypertension:
favorable effects of antioxidants and physical exercise.  Anti-
oxid Redox Signal 2005, 7(9–10):1356-1366.
43. De la Fuente M: Effects of antioxidants on immune system age-
ing.  Eur J Clin Nutr 2002, 56(Suppl 3):5-8.
44. Zelenay S, Moraes Fontes MF, Fesel C, Demengeot J, Coutinho A:
Physiopathology of natural auto-antibodies: the case for reg-
ulation.  J Autoimmun 2007, 29(4):229-235.
45. Pasic S, Micic D, Kuzmanovic M: Epstein-Barr virus-associated
haemophagocytic lymphohistiocytosis in Wiskott-Aldrich
syndrome.  Acta Paediatr 2003, 92(7):859-861.
46. Stejskal J, Stejskal VD: The role of metals in autoimmunity and
the link to neuroendocrinology.  Neuro Endocrinol Lett 1999,
20(6):351-364.
47. Bressler JP, Olivi L, Cheong JH, Kim Y, Maerten A, Bannon D: Metal
transporters in intestine and brain: their involvement in
metal-associated neurotoxicities.  Hum Exp Toxicol 2007,
26(3):221-229.
48. Yokel RA: Blood-brain barrier flux of aluminum, manganese,
iron and other metals suspected to contribute to metal-
induced neurodegeneration.  J Alzheimers Dis 2006, 10(2–
3):223-253.
49. Galaris D, Pantopoulos K: Oxidative stress and iron homeosta-
sis: mechanistic and health aspects.  Crit Rev Clin Lab Sci 2008,
45(1):1-23.
50. Wright RO, Baccarelli A: Metals and neurotoxicology.  J Nutr
2007, 137(12):2809-2813.
51. Donnelly PS, Xiao Z, Wedd AG: Copper and Alzheimer's dis-
ease.  Curr Opin Chem Biol 2007, 11(2):128-133.
52. Finkelstein Y, Milatovic D, Aschner M: Modulation of cholinergic
systems by manganese.  Neurotoxicology 2007, 28(5):1003-1014.
53. Valko M, Morris H, Cronin MT: Metals, toxicity and oxidative
stress.  Curr Med Chem 2005, 12(10):1161-1208.
54. Havarinasab S, Hultman P: Organic mercury compounds and
autoimmunity.  Autoimmun Rev 2005, 4(5):270-275.
55. HogenEsch H: Mechanisms of stimulation of the immune
response by aluminum adjuvants.  Vaccine 2002, 20(Suppl
3):34-39.
56. Casciola-Rosen L, Wigley F, Rosen A: Scleroderma autoantigens
are uniquely fragmented by metal-catalyzed oxidation reac-
tions: implications for pathogenesis.  J Exp Med 1997,
185(1):71-79.
57. Rosen A, Casciola-Rosen L, Wigley F: Role of metal-catalyzed
oxidation reactions in the early pathogenesis of sclero-
derma.  Curr Opin Rheumatol 1997, 9(6):538-543.
58. Wu Z, Turner DR, Oliveira DB: Antioxidants inhibit mercuric
chloride-induced early vasculitis.  Int Immunol 2002,
14(3):267-273.
59. Ehrenfeld M, Blank M, Shoenfeld Y, Hidvegi M: AVEMAR (a new
benzoquinone-containing natural product) administration
interferes with the Th2 response in experimental SLE and
promotes amelioration of the disease.  Lupus 2001,
10(9):622-627.
60. Comin-Anduix B, Boros LG, Marin S, Boren J, Callol-Massot C, Cen-
telles JJ, Torres JL, Agell N, Bassilian S, Cascante M: Fermented
wheat germ extract inhibits glycolysis/pentose cycle
enzymes and induces apoptosis through poly(ADP-ribose)
polymerase activation in Jurkat T-cell leukemia tumor cells.
J Biol Chem 2002, 277(48):46408-46414.
61. Hidvégi M, Ráso E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Effect of Avemar and Avemar + vitamin C on tumor growth
and metastasis in experimental animals.  Anticancer Res 1998,
18(4A):2353-2358.
62. Masuda T, Inaba Y, Maekawa T, Takeda Y, Tamura H, Yamaguchi H:
Recovery mechanism of the antioxidant activity from car-
nosic acid quinone, an oxidized sage and rosemary antioxi-
dant.  J Agric Food Chem 2002, 50(21):5863-5869.
63. Knedla A, Neumann E, Müller-Ladner U: Developments in the
synovial biology field 2006.  Arthritis Res Ther 2007, 9(2):209.
64. Hu F, Sun WW, Zhao XT, Cui ZJ, Yang WX: TRPV1 mediates cell
death in rat synovial fibroblasts through calcium entry-
dependent ROS production and mitochondrial depolariza-
tion.  Biochem Biophys Res Commun 2008, 16;369(4):989-93.
65. Cedergren J, Forslund T, Sundqvist T, Skogh T: Intracellular oxida-
tive activation in synovial fluid neutrophils from patients
with rheumatoid arthritis but not from other arthritis
patients.  J Rheumatol 2007, 34(11):2162-2170.
66. van Vugt RM, Rijken PJ, Rietveld AG, van Vugt AC, Dijkmans BA:
Antioxidant intervention in rheumatoid arthritis: results of
an open pilot study.  Clin Rheumatol 2008, 27(6):771-775.
67. Helmy M, Shohayeb M, Helmy MH, el-Bassiouni EA: Antioxidants as
adjuvant therapy in rheumatoid disease. A preliminary
study.  Arzneimittelforschung 2001, 51(4):293-298.
68. Dianzani U, Chiocchetti A, Ramenghi U: Role of inherited defects
decreasing Fas function in autoimmunity.  Life Sci 2003,
72(25):2803-2824.
69. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius
C, Finocchiaro M, Mangiameli A, Di Mauro M, Stella AM, Castellino P:
Oxidative stress and cellular stress response in diabetic
nephropathy.  Cell Stress Chaperones 2007, 12(4):299-306.
70. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella
R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA: Nitro-
sative stress, cellular stress response, and thiol homeostasis
in patients with Alzheimer's disease.  Antioxid Redox Signal 2006,
8(11–12):1975-1986.
71. Mancuso C, Perluigi M, Cini C, De Marco C, Giuffrida Stella AM, Cala-
brese V: Heme oxygenase and cyclooxygenase in the central
nervous system: a functional interplay.  J Neurosci Res 2006,
84(7):1385-1391.
72. Mancuso C: Heme oxygenase and its products in the nervous
system.  Antioxid Redox Signal 6(5):878-887.
73. Oliveira V, Agua-Doce A, Duarte J, Soares MP, Graca L: Regulatory
T cell maintenance of dominant tolerance: induction of tis-
sue self-defense?  Transpl Immunol 2006, 17(1):7-10.
74. Brusko TM, Wasserfall CH, Agarwal A, Kapturczak MH, Atkinson
MA: An integral role for heme oxygenase-1 and carbon mon-
oxide in maintaining peripheral tolerance by CD4+CD25+
regulatory T cells.  J Immunol 2005, 174(9):5181-5186.
75. Scapagnini G, Colombrita C, Amadio M, D'Agata V, Arcelli E, Sapienza
M, Quattrone A, Calabrese V: Curcumin activates defensive
genes and protects neurons against oxidative stress.  Antioxid
Redox Signal 2006, 8(3–4):395-403.
76. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ,
Motterlini R: Caffeic acid phenethyl ester and curcumin: a
novel class of heme oxygenase-1 inducers.  Mol Pharmacol 2002,
61(3):554-561.
77. Ames BN: Micronutrients prevent cancer and delay aging.
Toxicol Letters 1998, 102:103-105.
78. Liu RH: Potential synergy of phytochemicals in cancer pre-
vention: mechanism of action.  J Nutr 2004, 134(Suppl
12):3479S-3485S.
79. Owen RW, Haubner R, Wurtele G, Hull E, Spiegelhalder B, Bartsch
H: Olives and olive oil in cancer prevention.  Eur J Cancer Prev
2004, 13(4):319-326.
80. McCall MR, Frei B: Can antioxidant vitamins materially reduce
oxidative damage in humans?  Free Rad Biol Med 1999,
26:1034-1053.
81. Villamor E, Fawzi WW: Effects of vitamin a supplementation on
immune responses and correlation with clinical outcomes.
Clin Microbiol Rev 2005, 18(3):446-464.
82. Chew BP, Park JS: Carotenoid action on the immune response.
J Nutr 2004, 134(1 ):257S-261S.
83. Stephensen CB: Vitamin A, infection, and immune function.
Annu Rev Nutr 2001, 21:167-192.
84. Giray B, Kan E, Bali M, Hincal F, Basaran N: The effect of vitamin
E supplementation on antioxidant enzyme activities and
lipid peroxidation levels in hemodialysis patients.  Clin Chim
Acta 2003, 338(1–2):91-98.
85. Neuhouser ML, Patterson RE, Thornquist MD, Omenn GS, King IB,
Goodman GE: Fruits and vegetables are associated with lower
lung cancer risk only in the placebo arm of the beta-carotene
and retinol efficacy trial (CARET).  Cancer Epidemiol Biomarkers
Prev 2003, 12(4):350-358.Page 7 of 9
(page number not for citation purposes)
Nutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/2986. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS,
Zheng SF, Gail M, Li GY: Nutrition intervention trials in Linxian,
China: supplementation with specific vitamin/mineral com-
binations, cancer incidence, and disease-specific mortality in
the general population.  J Natl Cancer Inst 1993,
85(18):1483-1492.
87. Omenn GS: Chemoprevention of lung cancers: lessons from
CARET, the beta-carotene and retinol efficacy trial, and
prospects for the future.  Eur J Cancer Prev 2007, 16(3):184-191.
88. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR,
Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart
S, Cherniack MG, Brodkin CA, Hammar S: Risk factors for lung
cancer and for intervention effects in CARET, the Beta-Car-
otene and Retinol Efficacy Trial.  J Natl Cancer Inst 1996,
88(21):1550-1559.
89. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Mon-
tori VM: Efficacy of antioxidant supplementation in reducing
primary cancer incidence and mortality: systematic review
and meta-analysis.  Mayo Clin Proc 2008, 83(1):23-34.
90. Slatore CG, Littman AJ, Au DH, Satia JA, White E: Long-term use
of supplemental multivitamins, vitamin C, vitamin E, and
folate does not reduce the risk of lung cancer.  Am J Respir Crit
Care Med 177(5):524-30. 2008 Mar 1
91. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortal-
ity in randomized trials of antioxidant supplements for pri-
mary and secondary prevention: systematic review and
meta-analysis.  JAMA 297(8):842-57. 2007 Feb 28
92. Anonymous: The effect of vitamin E and beta carotene on the
incidence of lung cancer and other cancers in male smokers.
The Alpha-Tocopherol, Beta Carotene Cancer Prevention
Study Group.  N Engl J Med 1994, 330(15):1029-1035.
93. Palozza P, Serini S, Di Nicuolo F, Calviello G: Mitogenic and apop-
totic signaling by carotenoids: involvement of a redox mech-
anism.  IUBMB Life 2001, 52(1–2):77-81.
94. Palozza P, Serini S, Di Nicuolo F, Boninsegna A, Torsello A, Maggiano
N, Ranelletti FO, Wolf FI, Calviello G, Cittadini A: beta-Carotene
exacerbates DNA oxidative damage and modifies p53-
related pathways of cell proliferation and apoptosis in cul-
tured cells exposed to tobacco smoke condensate.  Carcino-
genesis 2004, 25(8):1315-1325.
95. Baker DL, Krol ES, Jacobsen N, Liebler DC: Reactions of beta-car-
otene with cigarette smoke oxidants. Identification of caro-
tenoid oxidation products and evaluation of the prooxidant/
antioxidant effect.  Chem Res Toxicol 1999, 12(6):535-543.
96. Palozza P, Serini S, Currò D, Calviello G, Igarashi K, Mancuso C:
beta-Carotene and cigarette smoke condensate regulate
heme oxygenase-1 and its repressor factor Bach1: relation-
ship with cell growth.  Antioxid Redox Signal 2006, 8(5–
6):1069-1080.
97. Li L, Grenard P, Nhieu JT, Julien B, Mallat A, Habib A, Lotersztajn S:
Heme oxygenase-1 is an antifibrogenic protein in human
hepatic myofibroblasts.  Gastroenterology 2003, 125(2):460-469.
98. Peyton KJ, Reyna SV, Chapman GB, Ensenat D, Liu XM, Wang H,
Schafer AI, Durante W: Heme oxygenase-1-derived carbon
monoxide is an autocrine inhibitor of vascular smooth mus-
cle cell growth.  Blood 2002, 99(12):4443-4448.
99. Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE, Choi AM: Car-
bon monoxide inhibits human airway smooth muscle cell
proliferation via mitogen-activated protein kinase pathway.
Am J Respir Cell Mol Biol 2002, 27(5):603-610.
100. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E,
Graça-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A,
Yamashita K, Bach FH: Bilirubin: a natural inhibitor of vascular
smooth muscle cell proliferation.  Circulation 2005,
112(7):1030-1039.
101. Anonymous: Vitamin E supplementation enhances immune
response in the elderly.  Nutr Rev 1992, 50(3):85-87.
102. Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxic-
ity.  Chem Res Toxicol 2008, 21(1):172-188.
103. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella
AM: Nitric oxide in the central nervous system: neuroprotec-
tion versus neurotoxicity.  Nat Rev Neurosci 2007, 8(10):766-775.
104. Calabrese V, Mancuso C, Ravagna A, Perluigi M, Cini C, De Marco C,
Butterfield DA, Stella AM: In vivo induction of heat shock pro-
teins in the substantia nigra following L-DOPA administra-
tion is associated with increased activity of mitochondrial
complex I and nitrosative stress in rats: regulation by glu-
tathione redox state.  J Neurochem 2007, 101(3):709-717.
105. Cassan C, Liblau RS: Immune tolerance and control of CNS
autoimmunity: from animal models to MS patients.  J Neuro-
chem 2007, 100(4):883-892.
106. McFarland HF, Martin R: Multiple sclerosis: a complicated pic-
ture of autoimmunity.  Nat Immunol 2007, 8(9):913-919.
107. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB,
Pierce WM, Booze R, Markesbery WR, Butterfield DA: Proteomic
identification of oxidatively modified proteins in Alzheimer's
disease brain. Part I: creatine kinase BB, glutamine synthase,
and ubiquitin carboxy-terminal hydrolase L-1.  Free Radic Biol
Med 2002, 33(4):562-571.
108. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR,
Butterfield DA: Proteomic identification of nitrated proteins in
Alzheimer's disease brain.  J Neurochem 2003, 85(6):1394-1401.
109. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C,
Sultana R: Elevated protein-bound levels of the lipid peroxida-
tion product, 4-hydroxy-2-nonenal, in brain from persons
with mild cognitive impairment.  Neurosci Lett 2006,
397(3):170-173.
110. Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A: Elevated pro-
tein carbonylation in the brain white matter and gray matter
of patients with multiple sclerosis.  J Neurosci Res 2005,
81(5):687-695.
111. Floor E, Wetzel MG: Increased protein oxidation in human sub-
stantia nigra pars compacta in comparison with basal ganglia
and prefrontal cortex measured with an improved dinitroph-
enylhydrazine assay.  J Neurochem 1998, 70(1):268-275.
112. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y:
Immunohistochemical detection of 4-hydroxynonenal pro-
tein adducts in Parkinson disease.  Proc Natl Acad Sci USA 1996,
93(7):2696-2701.
113. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG,
Montine TJ: Parkinson's disease is associated with oxidative
damage to cytoplasmic DNA and RNA in substantia nigra
neurons.  Am J Pathol 1999, 154(5):1423-1429.
114. Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafato S,
Puleo E, Pennisi G, Mancuso C, Butterfield DA, Stella AG: Redox
regulation of cellular stress response in aging and neurode-
generative disorders: role of vitagenes.  Neurochem Res 2007,
32(4–5):757-773.
115. Araujo DM, Lapchak PA: Induction of immune system media-
tors in the hippocampal formation in Alzheimer's and Par-
kinson's diseases: selective effects on specific interleukins
and interleukin receptors.  Neuroscience 1994, 61(4):745-754.
116. Ringheim GE, Conant K: Neurodegenerative disease and the
neuroimmune axis (Alzheimer's and Parkinson's disease,
and viral infections).  J Neuroimmunol 2004, 147(1–2):43-49.
117. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflam-
matory agents as possible protective factors for Alzheimer's
disease: a review of 17 epidemiologic studies.  Neurology 1996,
47(2):425-432.
118. Calabrese V, Butterfield DA, Stella AM: Nutritional antioxidants
and the heme oxygenase pathway of stress tolerance: novel
targets for neuroprotection in Alzheimer's disease.  Ital J Bio-
chem 2003, 52(4):177-181.
119. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Cala-
brese V: Nutritional approaches to combat oxidative stress in
Alzheimer's disease.  J Nutr Biochem 2002, 13(8):444.
120. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman
BA, Baranak CC, Rofecoxib Protocol 091 Study Group: Rofecoxib:
no effect on Alzheimer's disease in a 1-year, randomized,
blinded, controlled study.  Neurology 2004, 62(1):66-71.
121. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Far-
low MR, Jin S, Thomas RG, Thal LJ: Alzheimer's Disease Cooper-
ative Study. Effects of rofecoxib or naproxen vs placebo on
Alzheimer disease progression: a randomized controlled
trial.  JAMA 2003, 289(21):2819-2826.
122. Neary D, Snowden JS, Mann DM: Cognitive change in motor neu-
rone disease/amyotrophic lateral sclerosis (MND/ALS).  J
Neurol Sci 2000, 180(1–2):15-20.
123. Kiernan JA, Hudson AJ: Changes in sizes of cortical and lower
motor neurons in amyotrophic lateral sclerosis.  Brain 1991,
114(Pt 2):843-853.Page 8 of 9
(page number not for citation purposes)
Nutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/29Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
124. Roberts BR, Tainer JA, Getzoff ED, Malencik DA, Anderson SR,
Bomben VC, Meyers KR, Karplus PA, Beckman JS: Structural char-
acterization of zinc-deficient human superoxide dismutase
and implications for ALS.  J Mol Biol 2007, 373(4):877-890.
125. Kong J, Xu Z: Massive mitochondrial degeneration in motor
neurons triggers the onset of amyotrophic lateral sclerosis in
mice expressing a mutant SOD1.  J Neurosci 1998,
18(9):3241-3250.
126. Desnuelle C, Dib M, Garrel C, Favier A: A double-blind, placebo-
controlled randomized clinical trial of alpha-tocopherol
(vitamin E) in the treatment of amyotrophic lateral sclero-
sis. ALS riluzole-tocopherol Study Group.  Amyotroph Lateral
Scler Other Motor Neuron Disord 2001, 2(1):9-18.
127. Benatar M: Lost in translation: treatment trials in the SOD1
mouse and in human ALS.  Neurobiol Dis 2007, 26(1):1-13.
128. Orrell RW: AEOL-10150 (Aeolus).  Curr Opin Investig Drugs 2006,
7(1):70-80.Page 9 of 9
(page number not for citation purposes)
